Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity ...

Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...

The full-year cost of care for U.S. patients with obesity, two years after starting on Novo Nordisk's Wegovy or similar GLP-1 ...

The active ingredient in Ozempic and Wegovy has once again proven to have health effects outside of weight loss in a huge ...

Novo Nordisk is urging the U.S. Food and Drug Administration (FDA) to block ‘copycat’ versions of its popular weight-loss and ...

The University of California, Davis today announced an expanded collaboration with the BioInnovation Institute (BII) to ...

City employees in NYC had insurance coverage for GLP-1 drugs like Wegovy and Zepbound for less than a year before learning it ...

A new class of weight-loss drugs is changing the food industry, but not in the way many expected at first. They could present ...

In Quebec, anti-obesity medications are on the list of exclusions of the Régie de l’assurance maladie du Québec (RAMQ). Quebec is the only Canadian province that does not evaluate obesity medications ...

Economic data in Q3 indicated lower inflation and employment, prompting the Fed to cut interest rates by 50bps, influencing ...

In obesity, it will compete with Novo Nordisk’s GLP-1 agonist Wegovy (semaglutide), which launched in limited quantities in the UK last September and is also recommended by NICE. Novo Nordisk ...

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top ...